Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 19/20 | 0.81 |
| ▸ | CCNC | P24863 | 18/20 | 0.81 |
| ▸ | BPTF | Q12830 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620064 | 0.92 | CDK8 (0.81) | CDK8CCNCBPTF | |
| SCHEMBL16620062 | 0.92 | CDK8 (0.81) | CDK8CCNCBPTF | |
| SCHEMBL16619896 | 0.89 | CDK8 (1.00) | CDK8CCNCBPTF | |
| SCHEMBL16619894 | 0.89 | CDK8 (1.00) | CDK8CCNCBPTF | |
| SCHEMBL23815621 | 0.86 | CDK8 (0.93) | CDK8CCNC | |
| SCHEMBL16620147 | 0.85 | CDK8 (0.80) | CDK8CCNCBPTF | |
| SCHEMBL16629088 | 0.85 | CDK8 (0.80) | CDK8CCNCBPTF | |
| SCHEMBL16620056 | 0.84 | CDK8 (0.81) | CDK8CCNCBPTF | |
| SCHEMBL16629087 | 0.84 | CDK8 (0.81) | CDK8CCNCBPTF | |
| SCHEMBL16620274 | 0.83 | CDK8 (0.81) | CDK8CCNCBPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK8 1932/4885CCNC 2633/4885BPTF 166/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDK8 2297/4885CCNC 4208/4885BPTF 3457/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDK8 1464/4885CCNC 3141/4885BPTF 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.